GeoVax to Present Next-Generation COVID-19 Vaccine and Cancer Treatment Advances at Major Biotech Conference

Biotechnology company GeoVax Labs, Inc. (Nasdaq: GOVX) is preparing to present its strategic vision for 2025 at the upcoming BIO CEO & Investor Conference in New York, marking significant developments in both infectious disease vaccines and cancer treatments. The company's presentation comes at a crucial time as it advances multiple Phase 2 clinical trials for its next-generation COVID-19 vaccine, GEO-CM04S1.

The company's COVID-19 vaccine program has gained notable traction, recently securing a BARDA-funded contract for a 10,000-participant Phase 2b clinical trial. This development is particularly significant as GEO-CM04S1 aims to address critical gaps in current COVID-19 vaccination strategies, especially for immunocompromised patients and those requiring more durable booster protection.

Of particular importance is GeoVax's focus on vulnerable populations, including patients with hematologic cancers and chronic lymphocytic leukemia, for whom current COVID-19 vaccines may provide insufficient protection. This approach could represent a crucial advancement in protecting high-risk populations during the ongoing evolution of the pandemic.

Beyond infectious diseases, GeoVax is making strides in oncology with Gedeptin®, its therapy for advanced head and neck cancers. The company has completed a Phase 1/2 clinical trial and plans to initiate a Phase 2 trial combining Gedeptin with immune checkpoint inhibitors in mid-2025, potentially offering new hope for patients with recurring head and neck cancers.

These developments suggest a significant expansion of GeoVax's therapeutic portfolio, positioning the company to address major unmet needs in both infectious disease prevention and cancer treatment. The presentation at the BIO CEO & Investor Conference represents an important milestone in showcasing these advancements to the biotechnology investment community.